Across TCGA pan-cancer cohorts, H2BC11 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated H2BC11 data layer compared with 25 for mass-spec protein.
The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher H2BC11 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated H2BC11 expression acts as an unfavorable survival marker.
SKCM and BRCA are the cancer types where H2BC11 Mutation most reproducibly stratifies survival.